Graphite Bio hires Alethia Young as CFO; Gutry steps down as PFO/PAO

LENZ Therapeutics, Inc.

Alethia Young appointed CFO effective April 1, 2022; previously senior biotech analyst at Cantor Fitzgerald.
Base salary $450,000, target cash bonus 40% of salary, signing bonus $170,000.
Relocation assistance $50,000/quarter for 12 months; initial option grant of 350,000 shares.
Philip Gutry resigns as principal financial officer and principal accounting officer effective April 1, remains Chief Business Officer.
Ms. Young will oversee finance, investor relations, corporate communications, and corporate strategy.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alethia Young

Chief Financial Officer

LENZ · LENZ Therapeutics, Inc.

Effective: 2022-04-01
Filed: March 2, 2022, 6:59 PM ET

On March 2, 2022, Graphite Bio, Inc. (the “Company”) announced the hiring and appointment of Alethia Young as Chief Financial Officer.

Role change

Philip P. Gutry

principal financial officer and principal accounting officer

LENZ · LENZ Therapeutics, Inc.

Effective: 2022-04-01
Successor: Alethia Young
Filed: March 2, 2022, 6:59 PM ET

Effective as of April 1, 2022, Philip P. Gutry, who is currently serving as Chief Business Officer, Head of Finance & Investor Relations, principal financial officer and principal accounting officer of the Company, will resign from his positions as the Company’s Head of Finance & Investor Relations, principal financial officer and principal accounting officer and will continue to serve as Chief Business Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alethia Young was appointed as Chief Financial Officer at LENZ Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 2, 2022, Graphite Bio, Inc. (the “Company”) announced the hiring and appointment of Alethia Young as Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Philip P. Gutry resigned as principal financial officer and principal accounting officer at LENZ Therapeutics, Inc..

Action: resigned
Role: principal financial officer and principal accounting officer

Exact text from the filing

Effective as of April 1, 2022, Philip P. Gutry, who is currently serving as Chief Business Officer, Head of Finance & Investor Relations, principal financial officer and principal accounting officer of the Company, will resign from his positions as the Company’s Head of Finance & Investor Relations, principal financial officer and principal accounting officer and will continue to serve as Chief Business Officer.

View on SEC.gov

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-008273

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.